nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Generalised erythema—Cisplatin—testicular cancer	0.155	0.155	CcSEcCtD
Cisatracurium Besylate—Trauma—Bleomycin—testicular cancer	0.0369	0.0369	CcSEcCtD
Cisatracurium Besylate—Hypoxemia—Methotrexate—testicular cancer	0.0354	0.0354	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Ifosfamide—testicular cancer	0.0236	0.0236	CcSEcCtD
Cisatracurium Besylate—Wheezing—Bleomycin—testicular cancer	0.017	0.017	CcSEcCtD
Cisatracurium Besylate—Laryngospasm—Etoposide—testicular cancer	0.0159	0.0159	CcSEcCtD
Cisatracurium Besylate—Injury—Bleomycin—testicular cancer	0.0139	0.0139	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Etoposide—testicular cancer	0.0135	0.0135	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Methotrexate—testicular cancer	0.0133	0.0133	CcSEcCtD
Cisatracurium Besylate—Wheezing—Cisplatin—testicular cancer	0.0126	0.0126	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—testicular cancer	0.0112	0.0112	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Bleomycin—testicular cancer	0.0108	0.0108	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Ifosfamide—testicular cancer	0.0104	0.0104	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Cisplatin—testicular cancer	0.0097	0.0097	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Ifosfamide—testicular cancer	0.00926	0.00926	CcSEcCtD
Cisatracurium Besylate—Angioedema—Chlorambucil—testicular cancer	0.00906	0.00906	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Etoposide—testicular cancer	0.00889	0.00889	CcSEcCtD
Cisatracurium Besylate—Convulsion—Chlorambucil—testicular cancer	0.00859	0.00859	CcSEcCtD
Cisatracurium Besylate—Flushing—Bleomycin—testicular cancer	0.00818	0.00818	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Etoposide—testicular cancer	0.00818	0.00818	CcSEcCtD
Cisatracurium Besylate—Convulsion—Vinblastine—testicular cancer	0.00787	0.00787	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vinblastine—testicular cancer	0.00784	0.00784	CcSEcCtD
Cisatracurium Besylate—Erythema—Bleomycin—testicular cancer	0.00767	0.00767	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Ifosfamide—testicular cancer	0.00767	0.00767	CcSEcCtD
Cisatracurium Besylate—Flushing—Dactinomycin—testicular cancer	0.00763	0.00763	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Epirubicin—testicular cancer	0.00756	0.00756	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Ifosfamide—testicular cancer	0.0074	0.0074	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Etoposide—testicular cancer	0.00731	0.00731	CcSEcCtD
Cisatracurium Besylate—Erythema—Dactinomycin—testicular cancer	0.00716	0.00716	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—testicular cancer	0.00699	0.00699	CcSEcCtD
Cisatracurium Besylate—Flushing—Ifosfamide—testicular cancer	0.00699	0.00699	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Ifosfamide—testicular cancer	0.00683	0.00683	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Ifosfamide—testicular cancer	0.0068	0.0068	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Ifosfamide—testicular cancer	0.00679	0.00679	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Cisplatin—testicular cancer	0.00661	0.00661	CcSEcCtD
Cisatracurium Besylate—Erythema—Ifosfamide—testicular cancer	0.00656	0.00656	CcSEcCtD
Cisatracurium Besylate—Urticaria—Chlorambucil—testicular cancer	0.00643	0.00643	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Cisplatin—testicular cancer	0.00638	0.00638	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Bleomycin—testicular cancer	0.00626	0.00626	CcSEcCtD
Cisatracurium Besylate—Flushing—Cisplatin—testicular cancer	0.00603	0.00603	CcSEcCtD
Cisatracurium Besylate—Angioedema—Ifosfamide—testicular cancer	0.00599	0.00599	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Chlorambucil—testicular cancer	0.00596	0.00596	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Cisplatin—testicular cancer	0.00587	0.00587	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Cisplatin—testicular cancer	0.00585	0.00585	CcSEcCtD
Cisatracurium Besylate—Hypotension—Bleomycin—testicular cancer	0.00585	0.00585	CcSEcCtD
Cisatracurium Besylate—Pruritus—Chlorambucil—testicular cancer	0.00572	0.00572	CcSEcCtD
Cisatracurium Besylate—Convulsion—Ifosfamide—testicular cancer	0.00568	0.00568	CcSEcCtD
Cisatracurium Besylate—Hypertension—Ifosfamide—testicular cancer	0.00566	0.00566	CcSEcCtD
Cisatracurium Besylate—Erythema—Cisplatin—testicular cancer	0.00565	0.00565	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Bleomycin—testicular cancer	0.00558	0.00558	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00554	0.00554	CcSEcCtD
Cisatracurium Besylate—Flushing—Etoposide—testicular cancer	0.00552	0.00552	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinblastine—testicular cancer	0.00546	0.00546	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Etoposide—testicular cancer	0.0054	0.0054	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Etoposide—testicular cancer	0.00537	0.00537	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Etoposide—testicular cancer	0.00536	0.00536	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Ifosfamide—testicular cancer	0.00535	0.00535	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—testicular cancer	0.00532	0.00532	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Ifosfamide—testicular cancer	0.00525	0.00525	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Ifosfamide—testicular cancer	0.0052	0.0052	CcSEcCtD
Cisatracurium Besylate—Hypotension—Ifosfamide—testicular cancer	0.005	0.005	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Epirubicin—testicular cancer	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Urticaria—Bleomycin—testicular cancer	0.00498	0.00498	CcSEcCtD
Cisatracurium Besylate—Convulsion—Cisplatin—testicular cancer	0.0049	0.0049	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00478	0.00478	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Ifosfamide—testicular cancer	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Cisplatin—testicular cancer	0.00461	0.00461	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Bleomycin—testicular cancer	0.00461	0.00461	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.00461	0.00461	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Epirubicin—testicular cancer	0.00458	0.00458	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Cisplatin—testicular cancer	0.00452	0.00452	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Cisplatin—testicular cancer	0.0045	0.0045	CcSEcCtD
Cisatracurium Besylate—Convulsion—Etoposide—testicular cancer	0.00449	0.00449	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Cisplatin—testicular cancer	0.00448	0.00448	CcSEcCtD
Cisatracurium Besylate—Hypertension—Etoposide—testicular cancer	0.00447	0.00447	CcSEcCtD
Cisatracurium Besylate—Pruritus—Bleomycin—testicular cancer	0.00443	0.00443	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00438	0.00438	CcSEcCtD
Cisatracurium Besylate—Hypotension—Cisplatin—testicular cancer	0.00431	0.00431	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Dactinomycin—testicular cancer	0.0043	0.0043	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Epirubicin—testicular cancer	0.00425	0.00425	CcSEcCtD
Cisatracurium Besylate—Urticaria—Ifosfamide—testicular cancer	0.00425	0.00425	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—testicular cancer	0.00424	0.00424	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Etoposide—testicular cancer	0.00423	0.00423	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Etoposide—testicular cancer	0.00413	0.00413	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Cisplatin—testicular cancer	0.00411	0.00411	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Etoposide—testicular cancer	0.00411	0.00411	CcSEcCtD
Cisatracurium Besylate—Hypotension—Etoposide—testicular cancer	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Rash—Bleomycin—testicular cancer	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Bleomycin—testicular cancer	0.00394	0.00394	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Ifosfamide—testicular cancer	0.00394	0.00394	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—testicular cancer	0.00393	0.00393	CcSEcCtD
Cisatracurium Besylate—Pruritus—Ifosfamide—testicular cancer	0.00379	0.00379	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Etoposide—testicular cancer	0.00377	0.00377	CcSEcCtD
Cisatracurium Besylate—Rash—Dactinomycin—testicular cancer	0.00368	0.00368	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Cisplatin—testicular cancer	0.0034	0.0034	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Epirubicin—testicular cancer	0.0034	0.0034	CcSEcCtD
Cisatracurium Besylate—Rash—Ifosfamide—testicular cancer	0.00337	0.00337	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Ifosfamide—testicular cancer	0.00337	0.00337	CcSEcCtD
Cisatracurium Besylate—Urticaria—Etoposide—testicular cancer	0.00336	0.00336	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Epirubicin—testicular cancer	0.00328	0.00328	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—testicular cancer	0.00323	0.00323	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—testicular cancer	0.00322	0.00322	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—testicular cancer	0.00321	0.00321	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—testicular cancer	0.00314	0.00314	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Etoposide—testicular cancer	0.00311	0.00311	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—testicular cancer	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Flushing—Epirubicin—testicular cancer	0.0031	0.0031	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—testicular cancer	0.00303	0.00303	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Epirubicin—testicular cancer	0.00303	0.00303	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Epirubicin—testicular cancer	0.00301	0.00301	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Epirubicin—testicular cancer	0.00301	0.00301	CcSEcCtD
Cisatracurium Besylate—Pruritus—Etoposide—testicular cancer	0.00299	0.00299	CcSEcCtD
Cisatracurium Besylate—Rash—Cisplatin—testicular cancer	0.00291	0.00291	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Cisplatin—testicular cancer	0.00291	0.00291	CcSEcCtD
Cisatracurium Besylate—Erythema—Epirubicin—testicular cancer	0.0029	0.0029	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—testicular cancer	0.00286	0.00286	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—testicular cancer	0.0028	0.0028	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—testicular cancer	0.00279	0.00279	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—testicular cancer	0.00278	0.00278	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—testicular cancer	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—testicular cancer	0.00269	0.00269	CcSEcCtD
Cisatracurium Besylate—Rash—Etoposide—testicular cancer	0.00267	0.00267	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Etoposide—testicular cancer	0.00266	0.00266	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00262	0.00262	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—testicular cancer	0.00253	0.00253	CcSEcCtD
Cisatracurium Besylate—Convulsion—Epirubicin—testicular cancer	0.00252	0.00252	CcSEcCtD
Cisatracurium Besylate—Hypertension—Epirubicin—testicular cancer	0.00251	0.00251	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—testicular cancer	0.00248	0.00248	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—testicular cancer	0.00246	0.00246	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00245	0.00245	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Epirubicin—testicular cancer	0.00237	0.00237	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—testicular cancer	0.00237	0.00237	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—testicular cancer	0.00233	0.00233	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Epirubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—testicular cancer	0.00232	0.00232	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Epirubicin—testicular cancer	0.00231	0.00231	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Epirubicin—testicular cancer	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00227	0.00227	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—testicular cancer	0.00226	0.00226	CcSEcCtD
Cisatracurium Besylate—Hypotension—Epirubicin—testicular cancer	0.00221	0.00221	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—testicular cancer	0.00219	0.00219	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—testicular cancer	0.00215	0.00215	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—testicular cancer	0.00214	0.00214	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—testicular cancer	0.00213	0.00213	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Epirubicin—testicular cancer	0.00211	0.00211	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—testicular cancer	0.00205	0.00205	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—testicular cancer	0.00201	0.00201	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—testicular cancer	0.00195	0.00195	CcSEcCtD
Cisatracurium Besylate—Urticaria—Epirubicin—testicular cancer	0.00188	0.00188	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—testicular cancer	0.00187	0.00187	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—testicular cancer	0.00179	0.00179	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Epirubicin—testicular cancer	0.00175	0.00175	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—testicular cancer	0.00174	0.00174	CcSEcCtD
Cisatracurium Besylate—Pruritus—Epirubicin—testicular cancer	0.00168	0.00168	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—testicular cancer	0.00162	0.00162	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—testicular cancer	0.0016	0.0016	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—testicular cancer	0.00159	0.00159	CcSEcCtD
Cisatracurium Besylate—Pruritus—Doxorubicin—testicular cancer	0.00155	0.00155	CcSEcCtD
Cisatracurium Besylate—Rash—Epirubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Epirubicin—testicular cancer	0.00149	0.00149	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—testicular cancer	0.00138	0.00138	CcSEcCtD
